机译:21-39岁女性宫颈内皮内瘤阶段2(CIN2)保守管理后的临床结果
Division of Cancer Epidemiology and Genetics NCI NIH DHHS Bethesda Maryland.;
Division of Cancer Epidemiology and Genetics NCI NIH DHHS Bethesda Maryland.;
Division of Cancer Epidemiology and Genetics NCI NIH DHHS Bethesda Maryland.;
Regional Laboratory Kaiser Permanente Northern California Berkeley California.;
Regional Laboratory Kaiser Permanente Northern California Berkeley California.;
Regional Laboratory Kaiser Permanente Northern California Berkeley California.;
Division of Cancer Epidemiology and Genetics NCI NIH DHHS Bethesda Maryland.;
Division of Cancer Epidemiology and Genetics NCI NIH DHHS Bethesda Maryland.;
Department of Women's Health Kaiser Permanente Medical Care Program South Sacramento California.;
Regional Laboratory Kaiser Permanente Northern California Berkeley California.;
Department of Epidemiology and Population Health Albert Einstein College of Medicine Bronx New;
机译:21-39岁女性宫颈内皮内瘤阶段2(CIN2)保守管理后的临床结果
机译:丹麦宫颈上皮内肿瘤患者妇女保守管理:队列研究
机译:保守治疗宫颈上皮内瘤变2级后高级别宫颈异常的复发
机译:合奏特征为评估宫颈癌检测试验和人乳头瘤病毒基因型在检测高级宫颈上皮内瘤和宫颈癌中的疗效进行评估框架
机译:子宫颈共测可早期发现HIV阳性女性的上皮内瘤变
机译:一项以人群为基础的队列研究在管理不同的ASCUS女性中宫颈上皮内瘤变3级或浸润性癌的风险
机译:21-39岁女性宫颈内皮内瘤阶段2(CIN2)保守管理后的临床结果